Memgen

15 articles about Memgen

• Memgen Announces New Clinical Data on MEM-288 in Advanced/Metastatic NSCLC at ASCO 2023 Annual Meeting

  6/6/2023

  Memgen, Inc., a clinical-stage biotechnology company today announced updated clinical data from its first-in-human study of MEM-288, an oncolytic viral therapy, in patients with advanced/metastatic refractory non-small cell lung cancer.

• Memgen Reports Results From Its First-In-Human Clinical Trial of MEM-288 in Solid Tumors Refractory to Checkpoint Inhibitors at SITC 2022

  11/30/2022

  Memgen, Inc., a biopharmaceutical company developing potentially life-saving cancer immunotherapies, presented the first clinical data for MEM-288, its oncolytic viral therapy, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting in Boston, MA.

• 

  BioSpace Movers & Shakers, Nov. 19

  11/19/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Memgen Appoints Kevin M. Coveney as Chief Financial Officer

  11/17/2021

  Memgen, Inc., a clinical-stage biotechnology company developing potentially life-saving cancer immunotherapies, announced that Kevin M. Coveney, CPA, has been appointed Chief Financial Officer.

• Memgen Announces FDA Clearance of IND Application for MEM-288

  11/3/2021

  Memgen, Inc. announced that the U.S. Food and Drug Administration has accepted its investigational new drug application for MEM-288, the company’s wholly-owned cancer immunotherapy candidate for the treatment of multiple solid tumors.

• 

  FDA Approves Multiple Investigational New Drug Applications

  11/3/2021

  This week, the U.S. Food and Drug Administration accepted Investigational New Drug Applications for multiple companies, clearing the way for clinical development.

• ImmunoCellular Therapeutics And Memgen Announce Letter Of Intent For Potential Joint Immuno-Oncology Collaboration

  3/23/2017

• Memgen Announces Preclinical Results For Its ISF35 Cancer Immunotherapy With Checkpoint Inhibitors In Metastatic Melanoma

  11/18/2015

• Memgen Announces Upcoming Presentation for ISF35 in Chronic Lymphocytic Leukemia at 2011 Memgen Annual Meeting

  12/9/2011

• Memgen Announces Clinical and Preclinical Results for ISF35 in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma

  12/9/2010

• Memgen's ISF35 Sensitizes Leukemia Cells to Chemotherapy

  12/8/2009

• Memgen's Clinical Trial Results of ISF35 for Chronic Lymphocytic Leukemia Selected for Presentation at American Society of Hematology 2009 Annual Meeting

  12/1/2009

• Memgen Reports Positive Results for ISF35 in High-Risk Chronic Lymphocytic Leukemia

  6/4/2009

• Memgen's ISF35 Clinical Trial Featured at American Society of Clinical Oncology Annual 2009 Meeting

  5/26/2009

• Memgen's Clinical Results on Leukemia Selected for Presentation at 2008 American Society of Hematology Annual Meeting

  12/3/2008